Once-a-day Tacrolimus Conversion Study: The OneTAC Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT02545972
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Newark Beth Israel Medical Center
- Registry
-
NCT02545972
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT02545972. Allocation not applicable; no masking; primary purpose treatment. Start 2016-02 (registry gives no type); primary completion 2018-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Once-a-day Tacrolimus Conversion Study: The OneTAC Trial
- Acronym
- OneTAC
- Condition
- Heart Failure
- Intervention (Drug)
- tacrolimus extended release
- Lead sponsor
- Newark Beth Israel Medical Center
Record details
- Record id
cardio:ct-nct02545972- Content hash
567254fde4b9353a673baac74b922ddb42d121c9f23ccd2446721451d865c73b